Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Equity Ratio (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Equity Ratio for 10 consecutive years, with 0.92 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 18.25% year-over-year to 0.92, compared with a TTM value of 0.92 through Dec 2025, up 18.25%, and an annual FY2025 reading of 0.92, up 18.25% over the prior year.
  • Equity Ratio was 0.92 for Q4 2025 at VYNE Therapeutics, up from 0.87 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.92 in Q4 2025 and bottomed at 0.56 in Q2 2021.
  • Average Equity Ratio over 5 years is 0.78, with a median of 0.78 recorded in 2024.
  • The sharpest move saw Equity Ratio soared 81.37% in 2021, then fell 21.02% in 2023.
  • Year by year, Equity Ratio stood at 0.73 in 2021, then increased by 5.53% to 0.77 in 2022, then rose by 18.66% to 0.91 in 2023, then dropped by 14.3% to 0.78 in 2024, then increased by 18.25% to 0.92 in 2025.
  • Business Quant data shows Equity Ratio for VYNE at 0.92 in Q4 2025, 0.87 in Q2 2025, and 0.78 in Q1 2025.